1
|
Lu T, Freytag L, Narayana VK, Moore Z, Oliver SJ, Valkovic A, Nijagal B, Peterson AL, de Souza DP, McConville MJ, Whittle JR, Best SA, Freytag S. Matrix Selection for the Visualization of Small Molecules and Lipids in Brain Tumors Using Untargeted MALDI-TOF Mass Spectrometry Imaging. Metabolites 2023; 13:1139. [PMID: 37999235 PMCID: PMC10673325 DOI: 10.3390/metabo13111139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 11/03/2023] [Accepted: 11/07/2023] [Indexed: 11/25/2023] Open
Abstract
Matrix-assisted laser desorption/ionization mass spectrometry imaging allows for the study of metabolic activity in the tumor microenvironment of brain cancers. The detectable metabolites within these tumors are contingent upon the choice of matrix, deposition technique, and polarity setting. In this study, we compared the performance of three different matrices, two deposition techniques, and the use of positive and negative polarity in two different brain cancer types and across two species. Optimal combinations were confirmed by a comparative analysis of lipid and small-molecule abundance by using liquid chromatography-mass spectrometry and RNA sequencing to assess differential metabolites and enzymes between normal and tumor regions. Our findings indicate that in the tumor-bearing brain, the recrystallized α-cyano-4-hydroxycinnamic acid matrix with positive polarity offered superior performance for both detected metabolites and consistency with other techniques. Beyond these implications for brain cancer, our work establishes a workflow to identify optimal matrices for spatial metabolomics studies.
Collapse
Affiliation(s)
- Tianyao Lu
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
- Department of Medical Biology, University of Melbourne, Melbourne 3052, Australia
| | - Lutz Freytag
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
| | - Vinod K. Narayana
- Metabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia
| | - Zachery Moore
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
- Department of Medical Biology, University of Melbourne, Melbourne 3052, Australia
| | - Shannon J. Oliver
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
| | - Adam Valkovic
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
| | - Brunda Nijagal
- Metabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia
| | - Amanda L. Peterson
- Metabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia
| | - David P. de Souza
- Metabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia
| | - Malcolm J. McConville
- Metabolomics Australia, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Melbourne 3010, Australia
- Department of Biochemistry and Molecular Biology, Bio21 Institute of Molecular Science and Biotechnology, University of Melbourne, Melbourne 3010, Australia
| | - James R. Whittle
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
- Department of Medical Biology, University of Melbourne, Melbourne 3052, Australia
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne 3052, Australia
| | - Sarah A. Best
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
- Department of Medical Biology, University of Melbourne, Melbourne 3052, Australia
| | - Saskia Freytag
- Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne 3052, Australia
- Department of Medical Biology, University of Melbourne, Melbourne 3052, Australia
| |
Collapse
|
2
|
Praveen P, Kocan M, Valkovic A, Bathgate R, Hossain MA. Single chain peptide agonists of relaxin receptors. Mol Cell Endocrinol 2019; 487:34-39. [PMID: 30641102 DOI: 10.1016/j.mce.2019.01.008] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 01/08/2019] [Accepted: 01/10/2019] [Indexed: 12/16/2022]
Abstract
There are seven human relaxin family peptides that have two chains (A and B) and three disulfide bonds. The target receptors for four of these peptides are known as relaxin family peptide receptors, RXFP1-RXFP4. Detailed structure-activity relationship (SAR) studies of relaxin family peptides have been reported over the years and have led to the design of new analogs with agonistic and antagonistic properties. This review briefly summarizes the SAR of human relaxin 2 (H2 relaxin) and human relaxin 3 (H3 relaxin) leading to the design and development of single-B-chain only agonists, B7-33 and peptide 5. The physiological functions of these new peptides agonists in cellular and animal models are also described.
Collapse
Affiliation(s)
- Praveen Praveen
- Florey Institute for Neuroscience & Mental Health, VIC, Australia
| | - Martina Kocan
- Florey Institute for Neuroscience & Mental Health, VIC, Australia
| | - Adam Valkovic
- Florey Institute for Neuroscience & Mental Health, VIC, Australia
| | - Ross Bathgate
- Florey Institute for Neuroscience & Mental Health, VIC, Australia; Department of Biochemistry and Molecular Biology, University of Melbourne, VIC, Australia
| | - Mohammed Akhter Hossain
- Florey Institute for Neuroscience & Mental Health, VIC, Australia; School of Chemistry and Bio21, University of Melbourne, University of Melbourne, VIC, Australia.
| |
Collapse
|